Adding to the discussion, Drs. David Ball, Daniel Steinfort, and Susan Harden propose alternative approaches for the complex task of improving nodal staging. Read more
The Netherlands Cancer Institute’s Dr. Paul Baas was honored for his significant contributions to lung cancer research during the 2023 European Lung Cancer Congress. Read more
Consensus eluded 2023 European Lung Cancer Congress attendees during a debate on the best approach for NSCLC. Read more
ILCN Associate Editors Drs. Suresh Senan and Witold Rzyman add clinical perspective to surveillance frequency discussion. Read more
In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients. Read more
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC. Read more
In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field. Read more
Dr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients. Read more
During TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment. Read more
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more